中国临床医学2011，Vol.18Issue(4)：462-464,3.
按需腹腔灌注重组人血管内皮抑制素治疗胃癌腹水的临床观察
Clinical Observation of on-Demand Intraperitoneal Injection of Endostar on Advanced Gastric Cancers with Malignant Ascites
王志明 1刘天舒 1李倩 1冯艺 1庄荣源 1宋燕 1陈勇 1周宇红 1金文1
作者信息
- 1. 复旦大学附属中山医院肿瘤内科,上海200052
- 折叠
摘要
Abstract
Objective:To observe the clinical efficacy of on-demand injection of endostar (recombinant human endostatin, a new generation of anti-angiogenesis agent ) on ascites of advanced gastric cancers, and evaluate the safety and tolerability of intrap-eritoneal application of the endostar. Methods: Oral fluoropyrimidine were applied for 5 patients with advanced gastric cancer for maintenance therapy. During the procedure of maintenance therapy, the 5 patients emerged noticeable symptoms of ascites, but with stable tumor masses. Following a maximum release of peritoneal cavity fluid, endostar 30mg was injected into peritoneal cavity. Then palliative withdrawal of fluids and on-demand intraperitoneal injections of endostar were given according to the symptoms of abdominal distension, and to investigate its clinical efficacy, quality of life, loss of ascites protein, as well as toxicity. Results: Five cases of patients could be evaluated by its efficacy and safety. All patients were found to decrease a-mounts of peritoneal cavity fluid, reduce loss of ascites protein and improve their quality of life but without drug-related toxicity. Conclusions: On-demand intraperitoneal injection of endostatin can better control the malignant ascites, reduce the clinical symptoms, improve the patients quality of life in the patients with advanced gastric cancers. Clinical safety is better.关键词
重组人血管内皮抑制素/胃癌/腹水Key words
Recombinant human endostatin/Gastric cancer/Ascites分类
医药卫生引用本文复制引用
王志明,刘天舒,李倩,冯艺,庄荣源,宋燕,陈勇,周宇红,金文..按需腹腔灌注重组人血管内皮抑制素治疗胃癌腹水的临床观察[J].中国临床医学,2011,18(4):462-464,3.
